Disclosed is a pharmaceutical composition for the treatment of dry eye and/or corneal/conjunctival disorders. The pharmaceutical composition comprises a human serum albumin as an active ingredient, wherein the human serum albumin is produced by using a recombinant yeast produced by transforming an yeast with a gene encoding the human serum albumin. Also disclosed is a method for the treatment of dry eye and/or corneal/conjunctival disorders, which comprises administering an effective amount of a human serum albumin to a patient who needs the treatment of dry eye and/or corneal/conjunctival disorders, wherein the human serum albumin is produced by using a recombinant yeast produced by transforming an yeast with a gene encoding the human serum albumin.
